<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle><![CDATA[STTR Phase I:  Novel Inhaled Nitric Oxide Therapy For Pulmonary Treatments (COVID-19)]]></AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>08/01/2021</AwardEffectiveDate>
<AwardExpirationDate>07/31/2023</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>256000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>15030000</Code>
<Directorate>
<Abbreviation>TIP</Abbreviation>
<LongName>Dir for Tech, Innovation, &amp; Partnerships</LongName>
</Directorate>
<Division>
<Abbreviation>TI</Abbreviation>
<LongName>Translational Impacts</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Erik Pierstorff</SignBlockName>
<PO_EMAI>epiersto@nsf.gov</PO_EMAI>
<PO_PHON>7032922165</PO_PHON>
</ProgramOfficer>
<AbstractNarration><![CDATA[The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project relates to the unmet need for new and effective therapeutics that target the lung. This proposal outlines a novel treatment for the pulmonary manifestations of COVID-19; however, this technology will also find use in other acute pulmonary disorders, such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), emphysema, and cystic fibrosis. Currently the options for treatment of pulmonary disorders include supplemental oxygen, ventilators, or nitrous oxide (NO) gas, which is toxic and cumbersome to use. Current technology uses gaseous NO which is a toxic gas supplied in high pressure tanks and is present only when inhaling the gas. The proposed project will develop a long-lasting, inhaled NO delivery system to improve lung function of patients suffering from ARDS brought on by COVID-19 or other causes.&lt;br/&gt;&lt;br/&gt;This Small Business Technology Transfer Phase I project advances translation of a novel molecule which sequesters NO chemically as a stable solid and can be engineered to degrade at a controlled rate for in situ continuous release. This proposal develops NO donors with optimized performance and stability for pulmonary delivery.  Tasks include: develop and test libraries of NO donor compounds for the ability and rate of NO release; evaluate and select compounds with good solubility characteristics to formulate for aerosolization/ nebulization; test candidates for improvement of lung function in animal models.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.]]></AbstractNarration>
<MinAmdLetterDate>07/26/2021</MinAmdLetterDate>
<MaxAmdLetterDate>07/26/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2040043</AwardID>
<Investigator>
<FirstName>steven</FirstName>
<LastName>riesinger</LastName>
<PI_MID_INIT>W</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>steven W riesinger</PI_FULL_NAME>
<EmailAddress><![CDATA[sriesinger@medchempartners.com]]></EmailAddress>
<NSF_ID>000530970</NSF_ID>
<StartDate>07/26/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Vikas</FirstName>
<LastName>Anathy</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Vikas Anathy</PI_FULL_NAME>
<EmailAddress><![CDATA[vikas.anathy@med.uvm.edu]]></EmailAddress>
<NSF_ID>000826264</NSF_ID>
<StartDate>07/26/2021</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>MedChem Partners LLC</Name>
<CityName>LEXINGTON</CityName>
<ZipCode>024217965</ZipCode>
<PhoneNumber>7816762000</PhoneNumber>
<StreetAddress>99 HAYDEN AVE</StreetAddress>
<StreetAddress2><![CDATA[STE 210]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Massachusetts</StateName>
<StateCode>MA</StateCode>
<CONGRESSDISTRICT>05</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MA05</CONGRESS_DISTRICT_ORG>
<ORG_UEI_NUM>S93ZFQLD4ZC7</ORG_UEI_NUM>
<ORG_LGL_BUS_NAME>MEDCHEM PARTNERS LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_UEI_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[University of Vermont]]></Name>
<CityName>Burlington</CityName>
<StateCode>VT</StateCode>
<ZipCode>054051742</ZipCode>
<StreetAddress><![CDATA[89 Beaumont Avenue]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Vermont</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>00</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>VT00</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>008E</Code>
<Text>Gene and Drug Delivery</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>1982</Code>
<Text>BIOLOGICAL CHEMISTRY</Text>
</ProgramReference>
<ProgramReference>
<Code>9150</Code>
<Text>EXP PROG TO STIM COMP RES</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Fund>
<Code>01002122DB</Code>
<Name><![CDATA[NSF RESEARCH & RELATED ACTIVIT]]></Name>
<FUND_SYMB_ID>040100</FUND_SYMB_ID>
</Fund>
<FUND_OBLG>2021~256000</FUND_OBLG>
</Award>
</rootTag>
